Linked research, clinical, and regulatory source pathways.
Company profile
About Akoya Biosciences
Akoya Biosciences has been acquired by Quanterix to create an integrated platform for measuring biomarkers across blood and tissue. The company specializes in spatial biology solutions that enable high-plex spatial proteomics at single-cell resolution. Akoya's product portfolio includes the PhenoCycler-Fusion and PhenoImager platforms, which allow researchers to simultaneously visualize dozens of protein biomarkers in tissue samples. The company offers comprehensive assay panels including the PhenoCode Discovery panels covering immuno-oncology (60 markers), neurobiology, and metabolism, along with specialized software for spatial data analysis including inForm, phenoptr, and Phenochart. These solutions are designed for translational research and clinical workflows, supporting applications in oncology, neurology, immunology, and other therapeutic areas. The technology enables researchers to map tumor microenvironments, characterize immune cell architecture, and understand spatial relationships between cells and biomarkers. Akoya's platforms are built for clinical rigor with validated, reproducible results suitable for biomarker discovery, validation, and companion diagnostics development. The acquisition by Quanterix combines Akoya's tissue-based spatial proteomics capabilities with Quanterix's Simoa ultrasensitive liquid biomarker detection technology, creating a comprehensive solution for biomarker research from bench to bedside.
Company description Akoya Biosciences official website
Primary marketPathology & Laboratory Diagnostics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Akoya Biosciences?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Alzheimer's disease
- Cardiovascular disease
- Immuno-oncology
- Infectious disease
- Inflammatory diseases
- Neurodegenerative diseases
- Neurological disorders
- Tumor microenvironment analysis
Who it serves
- Academic research institutions
- Biotechnology companies
- Clinical research organizations
- Diagnostic laboratories
- Government research facilities
- Pharmaceutical companies
- University hospitals
Deployment & integration
Deployment information is currently being developed.
Geographic context
MarketsGlobal
Company sourceOfficial website
Company milestones
Platform expansion
Quanterix completed acquisition of Akoya Biosciences, creating first integrated platform for measuring biomarkers across blood and tissue continuum. Launch of PhenoImager HT 2.0 and PhenoCycler-Fusion 2.0 platforms.
Partnerships
Recorded partners
- CROs
- Diagnostics labs
- Lucent Diagnostics (subsidiary)
- Top 20 pharma companies
- Uman Diagnostics
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
No source-backed Company products are currently listed.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Spatial proteomic analysis in human Alzheimer's disease brains enables identification of microenvironment-dependent microglial cell states.Nature neuroscience · Jul 1, 2026
Spatial proteomics profiling reveals oncogene-specific immune niches and prognostic markers in NSCLC.American journal of respiratory and critical care medicine · Jun 26, 2026
MIF-CD74 signaling drives immune modulation in medulloblastoma.Neuro-oncology · May 1, 2026
Integration of imaging-based and sequencing-based spatial omics mapping on the same tissue section via DBiTplus.Nature methods · Jan 15, 2026
Depleting the Action of EZH2 through PI3K-mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer.Molecular cancer therapeutics · Oct 1, 2025
Multi-omic spatial profiling reveals the unique SARS-CoV-2 lung microenvironment and collagen VI as a predictive biomarker in severe COVID-19.The European respiratory journal · Sep 1, 2025
Clinical validation
Clinical-trial records
Evolution of Metabolic and Immune Dysfunction in In-transit MelanomaNCT04658303 · Mentioned · RECRUITING
Personalised Immunotherapy PlatformNCT06536257 · Mentioned · RECRUITING
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
90% coverage of major immune cell types
PhenoCode Discovery IO60 Human Protein Panel
85% coverage of key immune checkpoints
Immuno-oncology panel
16 samples per week at 60 biomarkers simultaneously
High throughput processing capability
<10% CVs across matrices
Precision and reproducibility
2,300+ instruments deployed globally
Combined Quanterix-Akoya platform
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Akoya Biosciences
Recent articles published on Akoya Biosciences's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Pathology & Laboratory Diagnostics
Companies applying AI to digital pathology, histopathology slide analysis, laboratory diagnostics, or biomarker discovery. Includes AI-powered interpretation of lab test results, at-home diagnostic devices with AI analysis, and platforms that analyze tissue samples or biological specimens to support clinical diagnosis.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.